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Objective. Myeloid derived suppressor cells (MDSCs) have been identified as 
immunosuppressive cells in tumor related inflammation. However, the pathogenesis of MDSCs 
for autoimmune disease has not been investigated yet. The aim of this study is to address 
whether MDSCs contribute to autoimmune organ injury in lupus prone mice. 
Methods. MDSCs were analyzed by flow cytometric staining of CD11b+ GR-1+ in MRL-Faslpr 
mice. CD4+ T cell proliferation assay was performed by the co-culture with CD11b+ GR-1+ 
splenocytes. The percentage of immunosuppressive cells was examined during disease 
progression. The expression of chemokine receptor on immunosuppressive cells was analyzed. 
Moreover, chemotaxis assay was performed. 
Results. CD11b+ GR-1low cells had a suppressive effect on CD4+ T cell proliferation, which was 
restored by an arginase-1 inhibitor. CD11b+ GR-1low cells increased in percentage during disease 
progression in kidney and blood. The number of migrated CD11b+ GR-1low cells increased in the 
presence of monocyte chemoattractant protein (MCP)-1/CCL2.  
Conclusion. We assessed the involvement of CD11b+ GR-1low cells in autoimmune disorder in 
MRL-Faslpr mice. These cells regulate immunological responses via CCL2/CCR2 signaling. 
The regulation of immunosuppressive monocytes may provide novel therapeutic strategy for 






 Myeloid derived suppressor cells (MDSCs), which show heterogeneous phenotypes including 
immature granulocytes, monocytes/macrophages (Mφ), dendritic cells (DCs) and early myeloid 
progenitors, have been originally identified as immunosuppressive cells in association with 
tumor expansion. These cells have been reported to express CD11b and GR-1 in mouse models 
(1-4). In tumor microenvironment, MDSCs inhibit T cell activation via arginase (ARG)-1 and 
nitric oxidase activation, resulting in tumor growth (4). Moreover, MDSCs play a critical role 
not only in neoplastic diseases but also in other conditions (5-8). However, the impacts of 
MDSCs on autoimmune disorder have not been elucidated. 
It has been reported that MDSCs exist in peripheral blood and may have immunosuppressive 
effects in patients with inflammatory bowel disease (8) and melanoma (9). These results 
indicated that MDSCs may regulate the immune response not only within accumulated organs, 
but also in systemically. Chemokine system plays critical roles for the migration as well as the 
activation in various types of cells. Regarding the chemotaxis of MDSCs, recent reports show 
C-C chemokine receptor 2 (CCR2) regulates the dynamics in tumor environment (10-12).  
Autoimmune diseases in MRL/MPJ-lpr/lpr (MRL-Faslpr) mice resemble to human systemic 
lupus erythematosus, characterized by the disregulation of both cellular and humoral immunity 
(13). In this model, CCR2 has been reported to contribute to the progression of autoimmune 
kidney injury, followed by the decreased number of macrophage (Mφ) (14). However, the 
pathogenesis of MDSCs, especially focused on CCR2 signaling, remains to be investigated. 
Moreover, it should be elucidated whether MDSCs regulate systemic inflammation as well as 
peripheral autoimmune organ injury in association with CCR2 signaling. 
The aim of the present study is to investigate the phenotype and function of CD11b+GR-1+ 
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cells in MRL-Faslpr mice and to identify the immunosuppressive cells. Moreover, the impact of 
CCR2 signaling on immunosuppressive cells was examined.  
 
 
Material and Methods 
Mice  
MRL-Faslpr mice were obtained from Charles River Japan Inc., Atsugi, Japan. All procedures 
employed in the animal experiments complied with the standards set out in the Guideline for the 
Care and Use of Laboratory Animals in Takara-machi Campus of Kanazawa University. 
 
Antibodies 
The following antibodies were used for flow cytometry ; fluorescein isothianate (FITC) 
conjugated rat anti-mouse CD11b antibody, phycoerythrin (PE) conjugated rat anti-mouse Gr-1 
antibody, allophycocyanin (APC) conjugated hamster anti-mouse CD11c antibody, APC 
conjugated rat anti-mouse CD45R/B220 antibody, biotin conjugated rat anti-mouse I-Ak 
antibody (BD Biosciences, San Diego, CA), APC conjugated rat anti-mouse F4/80 antibody 
(eBioscience, San Diego, CA). 
 
Immunohistochemical examination 
Tissues for immunoperoxydase staining were snap-frozen in OCT (Miles Scientific, 
Naperville, Illinois, USA) and stored at –80°C. CD11b positive cells were examined using 
biotin conjugated anti-mouse CD11b monoclonal antibodies (BD Biosciences). These positive 




Cell isolation and separation 
  A single cell suspension was obtained from the spleens, kidneys and bone marrow as 
described previously (15). Following cell isolation, red blood cells were lysed using FACS 
lysing solusion (BD Biosciences). CD4+ T cells and CD11b+ cells were purified from spleen 
using MACS beads (Miltenyi Biotec. Auburn. CA) according to the manufacture’s protocol. The 
purity of cells after separation was > 90 %. For separation of CD11b+ GR-1+ cells, the purified 
CD11b+ cells were resuspended in FACS buffer (1× PBS supplemented with 2mM EDTA and 
0.5% bovine serum albumin) and stained with anti CD11b Abs and anti GR-1 Abs. Various 
myeloid cell populations were sorted by FACSCalibur (BD Biosciences). Cell morphology was 
examined on May-Giemsa staining (DAKO) in each myeloid cell population.  
 
Flow cytometric analysis 
After single cells were collected as described above, the cells were suspended in FACS buffer. 
Then, cell surface markers were stained with 10% mouse serum blocking. The biotinylated 
antibodies were visualized with PerCP-Cy5.5 streptavidin (BD Biosciences). FACS data were 
acquired on FACSCalibur. The percentage of cells expressing cell surface marker were 
determined by analyzing a minimum of 50000 cells, using FlowJo software (Tree Star, Palo Alto, 
CA) 
 
In vitro cell culture experiment 
Splenic CD4+ T cells and CD11b+ GR-1+ cells were co-cultured as described previously (7). 
Briefly, CD4+ T cells and CD11b+ GR-1+ cells were purified from MRL-Faslpr mice at the age of 
12 weeks as described above. These cells were suspended in RPMI 1640 medium (Invitrogen, 
Carlsbad, CA) including 100 μg/ml streptomycin and 100 U/ml penicillin. Purified CD11b+ 
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GR-1+ cells were first treated with mitomycin C (Nacalai tesque Inc, Kyoto) at 10 μg/mL for 2 
hours at 37°C in 5% CO2 cell culture incubator. CD4+ T cells were stimulated by Bio coat anti 
mouse CD3 coated plate (BD Biosciences) at 1.5 × 106 cells/well. CD11b+ GR-1+ cells were 
added to CD4+ T cells at 1 : 1 or different ratios. To determine the impact of arginase 1 for 
CD11b+ GR-1+ cells, 0.5 mM N(omega)-hydroxy-nor-L-arginine (nor-NOHA) (Carbiochem, 
Gibbstown, NJ) was added in some experiments. After 48 h, 10 μg/well WST-1 (Premix WST-1 
Cell Proliferation Assay System; Takara Bio inc. Tokyo) was added into each well for 
proliferation assay, and cells were harvested for 4 h. The absorbance was measured at 450 nm 
with a reference wavelength 650 nm. The proliferative activity of the isolated CD11b+ GR-1+ 
cells was subtracted to determine the activity of CD4+ T cells.  
 
Chemotaxis assay 
 Isolated CD11b+ GR-1low splenocytes were resuspended at 5 × 106 cell/mL in RPMI 1640 
medium with 0.5 % BSA. The 60 μL cells were added into 8-μm pore size chemotaxis chamber 
(Chemotaxicell 96; Kurabou, Osaka). Lower chamber of 96-well plate (BD pharmingen) were 
filled with 100 μL of medium containing 10 ng/mL murine recombinant monocyte 
chemoattractant protein (MCP)-1 (R&D, Minneapolis, MN). The chamber was incubated for 2 
hours at 37°C in 5% CO2 cell culture incubator. The number of cells which migrated through the 
filter into lower chamber were counted using cell counter of FACScalibur.  
 
RT- PCR analysis  
  Total RNA was purified from isolated CD11b+ GR-1low splenocytes using RNeasy mini kit 
(Qiagen, Valencia, CA). Reverse transcription was performed with SuperScript II (Invitrogen). 
Multiple C-C chemokine receptor (CCR) expression was analyzed using MPCR kit for mouse 
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chemokine receptor CCR set-1 (Maxim Biotec, Inc., San Francisco, CA) according to 
manufacture’s instruction manual.   
 
Statistical Analyses 
The data represent the means ± SEM. Statistical significance was determined by ANOVA and 




MRL-Faslpr mice contained 3 distinct populations of CD11b+ GR-1+ cells, which showed the 
different character in morphology and phenotype. 
To determine whether MDSCs exist in MRL-Faslpr mice, flow cytometric analysis was 
performed at 10 weeks of age. CD11b+ GR-1+ cells contained three distinct populations, 
showing  CD11b+ GR-1high, CD11b+ GR-1int and CD11b+ GR-1low cells (Fig. 1 a). These 
populations comprised 5.9±1.0 %, 1.6±0.1 %, 4.6±0.3 %, respectively.  May-Giemsa stain 
exhibited that CD11b+ GR-1high cells had lobular shaped nuclei, whereas CD11b+ GR-1int and 
CD11b+ GR-1low cells were monocytic in morphology (Fig. 1 b). Phenotypic study revealed that 
CD11b+ GR-1high cells did not express F4/80, CD11c nor B220. CD11b+ GR-1int cells expressed 
F4/80, but did not express CD11c nor B220. Part of CD11b+ GR-1low cells expressed F4/80, 
CD11c and B220 (Fig. 1 c). These data suggested that CD11b+ GR-1high cells were granulocyte 
lineage and that CD11b+ GR-1int cells were F4/80+ macrophage lineage. CD11b+ GR-1low cells 
contained heterogeneous populations.  
 
CD11b+ GR-1low cells suppress T cell proliferation via ARG-1 activity.  
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 To investigate whether CD11b+ GR-1+ cells from MRL-Faslpr mice have inhibitory effects on T 
cell proliferation, each population of CD11b+ GR-1+ cells was cultured with CD4+ T cells at the 
ratio of 1:1 in anti mouse CD3 coated plate (Fig. 2 a). CD11b+ GR-1high cells had no effect on 
CD4+ T cells proliferation, whereas CD11b+ GR-1int cells significantly induced the proliferation 
of CD4+ T cells as compared to CD4+ T cells cultured alone (CD4 only; 0.09±0.01, CD4 + 
CD11b+ GR-1high cells; 0.08±0.02, CD4 + CD11b+ GR-1int cells; 0.40±0.10). In contrast, CD11b+ 
GR-1low cells significantly inhibited the proliferation of CD+4 T cells (0.03±0.01) (Fig. 2 a). At 
the increased ratio of CD11b+ GR-1low cells to CD4+ T cells, 2 : 1, the proliferation of CD4+ T 
cells were completely suppressed (CD4 only; 0.38±0.02, CD4 + 2 X CD11b+ GR-1low cells; 
0.01±0.00) (Fig. 2 b). However, no inhibitory effect of CD11b+ GR-1low cells was shown at the 
ratio of 0.2 : 1(0.36±0.01) (Fig. 2 b). To determine the impact of ARG-1 on inhibitory effects of 
CD11b+ GR-1low cells, the cultured cells were treated with 0.5 mM nor-NOHA, an ARG-1 
inhibitor. The supplementation of nor-NOHA restored T cell proliferation (0.25±0.04) (Fig. 2 b). 
These results implicated that CD11b+ GR-1low cells had the inhibitory effect on CD4+ T cell 
proliferation via ARG-1 activation in MRL-Faslpr mice. 
 
The percentage of CD11b+ GR-1low cells changed according to disease activity in MRL-Faslpr 
mice. 
  MRL-Faslpr mice show glomerular, tubular and perivascular lesion at 22 weeks age (Fig. 3). 
To detect the localization of CD11b+ cells in peripheral organs, immunohistochemistry was 
performed on the spleens and kidneys at 22 weeks age. In the spleens, CD11b+ cells were 
detected at perifollicular lesion (Fig. 3 a). In the kidneys, CD11b+ cells were observed at 
perivascular lesion (Fig. 3 b) as well as within glomeruli (Fig. 3 c). The percentage of CD11b+ 
GR-1low cells in spleen, bone marrow, kidney and peripheral blood was analyzed during the 
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disease progression in MRL-Faslpr mice. In the spleen and the bone marrow, the percentage of 
CD11b+ GR-1low cells significantly increased in early stage of the disease, then decreased 
according to disease activity (Fig. 3 d, e). In spleen, CD11b+ GR-1low cells increased from 
3.5±0.1 % of all splenocytes at 6 weeks of age, to 4.6±0.3 % at 10 weeks of age, then decreased 
to 2.7±0.5 % at 22 weeks of age. In bone marrow, CD11b+ GR-1low cells increased from 
6.7±1.0 % at 6 weeks of age, to 10.8±0.9 % at 14 weeks of age, then decreased to 8.1±0.3 % at 
22 weeks of age. In contrast, the percentage of CD11b+ GR-1low cells increased during disease 
progression in the kidney and the blood (Fig. 3 f, g). The percentage increased from 0.1±0.0 % 
of all kidney cells at 6 weeks of age, to 2.0±0.2 % at 22 weeks of age, and from 2.2±0.5 % at 6 
weeks of age, to 15.2±2.8 % at 22 weeks of age in the blood. In MRL++ mice, the frequency of 
CD11b+ GR-1low cells did not change in these organs. 
 
CCR2 signaling contributed to the migration of CD11b+ GR-1low cells. 
 To examine whether CCR2 contributes to the chemotaxis of CD11b+ GR-1low cells in 
MRL-Faslpr mice, the expression of CCR2 and MCP-1/CCL2 induced chemotaxis assay were 
examined. Multiple chemokine receptor expression analysis revealed that CD11b+ GR-1low cells 
expressed strongly CCR4, CCR5 and weakly CCR2 mRNAs (Fig.4 a). In the chemotaxis assay, 
MCP-1/CCL2 induced chemotaxis of CD11b+ GR-1low cells (CD11b+ GR-1low cells alone; 
1125±41/well, MCP-1/CCL2 added; 1434±25/well) (Fig.4 b).  
 
Discussion 
  In various tumor models, the critical role of MDSCs has been reported. However, the impact 
of MDSCs on inflammatory disease, especially for the autoimmune organ disease, has not been 
examined yet. In this study, the proliferation of CD4+ T cells was markedly inhibited by the 
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co-cultured with CD11b+ GR-1low cells and restored by ARG-1 inhibitor. These cells were 
monocytic in morphology and showed heterogeneous populations in phenotype. In spleen and 
bone marrow, the percentage of CD11b+ GR-1low cells was increased in early stage of the disease. 
In kidney and peripheral blood, the percentage of CD11b+ GR-1low cells increased according to 
disease activity. CCL2/CCR2 signaling contributed to the migration of CD11b+ GR-1low cells. 
Taken all together, these results suggested CD11b+ GR-1low cells as immunosuppressive cells 
and may contribute to autoimmune response in MRL-Faslpr mice via CCL2/CCR2 signaling. 
  CD11b+ GR-1+ cells contained 3 distinct populations in MRL-Faslpr mice. Based on 
morphology and cell surface markers, CD11b+ GR-1high cells are granulocyte lineage. These 
cells showed no effects on CD4+ T cells in functional assay. CD11b+ GR-1int cells express F4/80 
and activated CD4+ T cells proliferation, indicating this population as Mφ lineage. CD11b+ 
GR-1low cells had the suppressive effect on CD4+ T cells. Therefore, this subset may be 
responsible for immunosuppressive cells in MRL-Faslpr mice. Supporting this notion, some 
reports exhibited suppressive effects of CD11b+ GR-1low cells in tumor mice models (11, 17). 
Moreover, the L-arginine metabolism is one of the mechanisms of MDSCs to suppress T cell 
function (4). In this regard, ARG-1 inhibitor restored CD4+ T cells function, which was cultured 
with CD11b+ GR-1low cells in the present study. In addition, CD11b+ cells were detected in 
perifollicular lesion of the spleen, indicating that CD11b+ cells interact with T cells. These 
results may indicate CD11b+ GR-1low cells as MDSCs in MRL-Faslpr mice. However, recent 
report showed CD11b+ GR-1- F4/80+ monocytes, which expressed arginase 1, as 
immunosuppressive M2 Mφ (18-20). Moreover, tumor-infiltrating MDSCs have been reported 
to bear M1 and M2 Mφ characteristics (11). Therefore, it remains to be resolved to determine 
distinct and defined markers between MDSCs and M2 Mφ. 
  The percentage of CD11b+ GR-1low cells increased at 10 weeks of age in spleen, kidney and 
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blood, suggesting these cells contribute to immune modulation in MRL-Faslpr mice. Zhu et al. 
reported that the percentage of MDSCs in peripheral organs increased after disease induction in 
experimental autoimmune encephalomyelitis (7). In alopecia areata mice, the injection of 
MDSCs has been reported to promote hair growth, resulting from inhibiting T cell function (6). 
These results, together with our present results, indicated that MDSCs play an important role not 
only in neoplastic diseases but also in inflammatory diseases. 
  In vitro study, the low expression of CCR2 mRNAs was detected on CD11b+ GR-1low cells. 
Moreover, MCP-1/CCL2 induced chemotaxis of CD11b+ GR-1low cells. Suggesting this notion, 
recent reports revealed that some chemokine receptors, including CCR2, CCR5 and CX3CR1 
were expressed on MDSCs and contribute to chemotaxis (10-12). 
In conclusion, we assessed the involvement of CD11b+ GR-1low cells, which were responsible 
for CD4+ T cell suppression in MRL-Faslpr mice. Immunosuppressive monocytes regulated 
immunological responses via CCR2 signaling. Further, the regulation of immunosuppressive 
monocytes may provide novel therapeutic strategy for organ damage in autoimmune diseases. 
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Morphology and phenotype of CD11b+GR-1+ cells in spleen of MRL-Faslpr mice. (a) Three 
distinct populations of CD11b+ GR-1+ cells were identified in the spleen of MRL-Faslpr mice. 
They are CD11b+ GR-1high, CD11b+ GR-1int and CD11b+ GR-1low populations. (b) May-Giemsa 
stain exhibited that CD11b+ GR-1high cells have lobular shaped nuclei, whereas CD11b+ GR-1int 
and CD11b+ GR-1low cells were monocytic in morphology. (c) Phenotypic study revealed that 
CD11b+ GR-1high cells do not express F4/80, CD11c nor B220. CD11b+ GR-1int cells express 
F4/80, but not express CD11c nor B220. Part of CD11b+ GR-1low cells express F4/80, CD11c 




To investigate whether CD11b+ GR-1+ cells from MRL-Faslpr mice have inhibitory effect on T 
cell proliferation, each population of CD11b+ GR-1+ cells was co-cultured with CD4+ T cells at 
the ratio of 1:1 in anti mouse CD3 coated plate. (a) CD11b+ GR-1high cells had no effect to CD4+ 
T cells proliferation, whereas CD11b+ GR-1int cells induced the proliferation of CD4+ T cells as 
compared to CD4+ T cells cultured alone. In contrast, CD11b+ GR-1low cells inhibit the 
proliferation of CD4+ T cells. (b) At the increased ratio of CD11b+ GR-1low cells to CD4+ T cells, 
2 : 1, the proliferation of CD4+ T cells were completely suppressed. However, the inhibitory 
effect of CD11b+ GR-1low cells were not shown at the ratio of 0.2 : 1. Moreover, the 
supplementation of nor-NOHA, an ARG-1 inhibitor, restored T cell proliferation. The 
proliferative activity of the isolated CD11b+ GR-1+ cells was subtracted to determine the activity 





The localization of CD11b+ cells and the time course of CD11b+ GR-1low cells were examined in 
MRL-Faslpr mice. MRL-Faslpr mice show glomerular hypercellurality, tubular damage 
(dilatation and casts;*) and perivascular cell infiltration (arrow heads) at 22 weeks age. 
(magnification: ×200) (a) In the spleens, CD11b+ cells were detected at perifollicular lesion. 
(magnification: ×100) (b) In the kidneys, CD11b+ cells were observed at perivascular lesion. 
(magnification: ×100) (c) CD11b+ cells also localized within glomeruli. (magnification: ×400) 
Frozen sections were stained with the indirect avidin-biotinylated peroxidase complex method. 
(d, e) In the spleen and the bone marrow, the frequency of CD11b+ GR-1low cells was 
significantly increased in early stage of the disease, then decreased according to disease activity. 
(f, g) In contrast, the frequency of CD11b+ GR-1low cells was increased during disease 




To test the impact of chemokine receptor for the function of MDSCs, the expression of 
chemokine receptor and the functional assays were performed. (a) Multiple PCR analysis for 
chemokine receptor revealed that CD11b+ GR-1low cells expressed strongly CCR4, CCR5 and 
weakly CCR2 mRNAs. (b) In the chemotaxis assay, MCP-1/CCL2 induced chemotaxis of 
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